| Intervention | Baseline characteristics (%) | N | Free survival without progression (median/months) | Partial response (%) | Stable disease (%) |
| Axitinib [235] | Papillary (50), medullary (18), follicular/Hurthle (25/18), anaplastic (3) | 60 | 18.1 | 30 | 48 |
| Axitinib [236] | Well differentiated thyroid cancer (71), medullary (29) | 41 |
| 34 | 25 |
| Motesanib [237] | Papillary (61), follicular/Hurthle (34) | 93 | 10 | 14 | 67 |
| Pazopanib [238] | Differentiated thyroid cancer (progression in <6 months) | 37 | 12 | 49 |
|
| Selumetinib [239] | Papilla with or without follicular elements (100) | 39 | 8 | 3 | 54 |
| Sorafenib/temsirolimus [240] | Papillary (62), follicular/Hurthle (14), poorly differentiated (16), anaplastic (3) | 37 |
| 22 | 57 |
| Sunitinib [241] | Differential thyroid cancer (74%), medullary (26) | 51 |
| 17 | 74 |
| Vandetanib [242] | Papillary (40), follicular (13), poorly differentiated (47) | 72 | 11.1 | 1 | 56 |